Cambridge, Massachusetts, United States
7K followers 500+ connections

Join to view profile
Versant NewCo

About

Track record in achieving milestones from target discovery through IND submission to…

Activity

Join now to see all activity

Experience & Education

  • Versant NewCo

View Klaus’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Publications

  • Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors

    -

    Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua CC, Cui H, Dipasquale AG, Friedman LS, Heise C, Koeppen H, Kotey A, Mintzer R, Oh A, Roberts DA, Rouge L, Rudolph J, Tam C, Wang W, Xiao Y, Young A, Zhang Y, Hoeflich KP.
    J Med Chem. 2014; 57(3):1033-45.

  • Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

    -

    Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, Holcomb T, Dijkgraaf P, Johnson S, Koeman J, Minna JD, Gazdar AF, Stern HM, Hoeflich KP, Wu TD, Settleman J, de Sauvage FJ, Gentleman RC, Neve RM, Stokoe D, Modrusan Z, Seshagiri S, Shames DS, Zhang Z.
    Genome Res. 2012;22(12):2315-27.

  • Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.

    -

    Rudolph J, Aliagas I, Crawford JJ, Mathieu S, Lee W, Chao Q, Dong P, Rouge L, Wang W, Heise C, Murray LJ, La H, Liu Y, Manning G, Diederich F, Hoeflich KP.
    ACS Med Chem Lett. 2015;6(6):711-5.

  • Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

    -

    Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, Ludlam MJ, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M.
    Nature. 2013 Sep 12;501(7466):232-6.

  • Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.

    -

    Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, Hoeflich KP, Singh M.
    Mol Cancer Ther. 2015 Jan;14(1):40-7.

  • P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma

    -

    Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, Koeppen H, Hoeflich KP.
    J Natl Cancer Inst. 2013 May 1;105(9):606-7.

  • PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

    -

    Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP.
    J Pathol. 2014 Dec;234(4):502-13.

  • Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

    -

    Kirkpatrick DS, Bustos DJ, Dogan T, Chan J, Phu L, Young A, Friedman LS, Belvin M, Song Q, Bakalarski CE, Hoeflich KP.
    Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19426-31.

  • Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics

    -

    Gnad F, Young A, Zhou W, Lyle K, Ong CC, Stokes MP, Silva JC, Belvin M, Friedman LS, Koeppen H, Minden A, Hoeflich KP.
    Mol Cell Proteomics. 2013 Aug;12(8):2070-80.

  • Targeting cancer with kinase inhibitors.

    -

    Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP.
    J Clin Invest. 2015;125(5):1780-9.

Join now to see all publications

Organizations

  • American Association for Cancer Research

    -

    2012-2015 AACR Pancreatic Cancer Research Grants Scientific Review Committee 2012-2013 Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee 2009 AACR Program Committee for Understanding and Targeting Oncogenic Pathways Symposium 2003-present Member, American Association for Cancer Research

More activity by Klaus

View Klaus’ full profile

  • See who you know in common
  • Get introduced
  • Contact Klaus directly
Join to view full profile

Explore more posts

Explore top content on LinkedIn

Find curated posts and insights for relevant topics all in one place.

View top content

Add new skills with these courses

See all courses